Why Lexicon Pharmaceuticals Stock Is Back in Focus

Lexicon Pharmaceuticals (LXRX) has drawn fresh attention after completing enrollment in its Phase III SONATA HCM trial for sotagliflozin and setting clear timelines for topline data and regulatory resubmissions.

Investors are also watching the company as its partner Viatris pursues regulatory approvals for sotagliflozin in markets outside the U.S. and Europe, which could influence how traders think about Lexicon Pharmaceuticals stock.

Against this backdrop, Lexicon Pharmaceuticals shares trade at US$2.34, with a 30 day share price return of 10.38% and a year to date share price return of 105.26%. The 1 year total shareholder return is 98.31%, suggesting momentum has been building around recent trial and regulatory updates despite quarterly losses and fresh shelf registrations announced on 6 August 2026.

If this kind of clinical and regulatory catalyst interests you, it can be useful to scan for other potential opportunities in healthcare. One place to start is with 44 healthcare AI stocks.

After a sharp run in Lexicon Pharmaceuticals on trial and regulatory news, the stock now sits closer to recent highs. Do the current earnings losses and fresh shelf registrations still leave enough upside to justify the risk?

Most Popular Narrative: 38% Undervalued

The most followed Lexicon Pharmaceuticals narrative sets a fair value of $3.77 per share, which sits well above the recent $2.34 close and assumes meaningful progress across the pipeline.

Lexicon Pharmaceuticals is focused on advancing its pipeline of novel medicines, including progressing pilavapadin into pivotal trials as a first novel oral non-opioid treatment for diabetic peripheral neuropathic pain in over two decades, which could significantly impact future revenue growth and market share. The company is developing LX9851, a first-in-class oral ACSL5 inhibitor for obesity and related cardiometabolic disorders, with promising preclinical data, which could open new revenue streams and target high-demand markets once the IND is submitted in 2025.

Want to understand why this narrative still reaches a higher fair value despite ongoing losses? The crux is a bold mix of revenue growth, margin recovery and a rich future earnings multiple that is far above typical pharma peers. The detailed blueprint is already mapped out. The numbers behind it are where the real story starts.

Result: Fair Value of $3.77 (UNDERVALUED)

However, Lexicon Pharmaceuticals still faces meaningful risks if costly trials disappoint or if dependence on partners like Viatris and Novo Nordisk disrupts expected milestone and royalty flows.

Another View On Lexicon Pharmaceuticals Valuation

The analyst narrative frames Lexicon Pharmaceuticals as 38% undervalued based on future earnings and a rich P/E multiple. However, the current P/S ratio of 25.1x tells a very different story. It sits well above the US Pharmaceuticals industry at 5x, the peer average at 6.4x, and a fair ratio of 9.5x.

This gap points to meaningful valuation risk if expectations around revenue growth or margins are not met. For an investor weighing the story against the current share price, the question is simple: Is the premium P/S multiple a sign of genuine opportunity or a lot of optimism baked in already?

Next Steps

With Lexicon Pharmaceuticals attracting mixed reactions, it makes sense to move quickly and check the underlying data yourself. Start by weighing 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Lexicon Pharmaceuticals?

You have seen how quickly sentiment can shift around Lexicon Pharmaceuticals. Do not stop here. Broaden your watchlist and keep fresh ideas on your radar.

• Pinpoint potential bargains early by scanning screener containing 18 high quality undiscovered gems that combine strong fundamentals with limited market attention.
• Strengthen your core holdings with solid balance sheet and fundamentals stocks screener (49 results) that prioritise resilient finances and disciplined capital management.
• Reduce portfolio stress by focusing on 88 resilient stocks with low risk scores that score well on stability and measured volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.